Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )
5 Jun 2022
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre,  Manhattan, USA )
5 Jun 2022
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides be...
Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )
5 Jun 2022
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )
5 Jun 2022
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC
Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significanc...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosf...
Dr Julie Gralow- Chief Medical Officer, ASCO
Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )
5 Jun 2022
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for...
Dr Martin McCabe- University of Manchester, Manchester, England
Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )
5 Jun 2022
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )
5 Jun 2022
(RVd) ± , stem cell transplantation and R maintenance shows significance for new...
Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA
(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory ewing...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 D...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
5 Jun 2022